MarginProbe® Identified as Successful Intraoperative Margin Assessment Technique During the Miami Breast Cancer Conference

Paoli, PA, March 17, 2016 – Dune Medical Devices’ MarginProbe was highlighted as an effective tool to help surgeons achieve clean margins during breast cancer surgery at the recent Miami Breast Cancer Conference.

The Miami Breast Cancer Conference, which was held on March 10-13, 2016, featured a presentation from J. Michael Dixon, MD, Western General Hospital, Clinical Director, Breakthrough Breast Cancer Research Unit and Honorary Professorship in Breast Surgery, University of Edinburgh. Dr. Dixon’s seminar, entitled Intraoperative Margin Assessment, addressed the ongoing concern among surgeons who ask, “Did I get it all?” when performing breast conserving surgeries.

Dr. Dixon, who has no affiliation with Dune Medical, pointed out that the rate of re-excision after breast conserving surgery is often as high as 46 percent for ductal carcinoma in situ (DCIS). He suggested that the ‘major reason a surgeon fails to completely excise cancers is that the disease is not completely imaged preoperatively. Furthermore, as the rate of DCIS increases, so does the rate of re-excision’. Other than removing all the surrounding tissue — which often results in cosmetic issues — traditional techniques including frozen sections, touch-prep cytology and high-frequency ultrasound techniques can help surgeons get clean margins but to varying degrees. Dr. Dixon also discussed other devices that look at the margins microscopically, however none of them are currently FDA approved.

One of the most effective tools, according to Dr. Dixon, is radiofrequency (RF) spectroscopy. Dr. Dixon highlighted Dune Medical’s MarginProbe, the first and only FDA-approved device used to enable real- time detection of cancer at the surface of excised tissue specimens, as helping to significantly decrease the need for second surgeries.

“Studies continue to show there is a direct correlation between the amount of tissue taken and cosmesis,” said Dixon. “There is a significant need for better technology for targeted margins from the traditional methods and MarginProbe is the first device that has received FDA approval that meets this need.”

This was welcome news for breast cancer surgeons according to Dune Medical’s U.S. President Lori Chmura.

“At each of these industry meetings and events, we hear the same things from surgeons: How do we know that we got it all? and We need a better technique for targeted margins,” said Chmura. “Having a proven technology like MarginProbe available to the medical community to help give their patients the confidence that they will get it all in the first surgery is a welcome tool in the fight against breast cancer.”

Dr. Dixon’s comments come on the heels of a recently published research study which found that the number of women who required a re-excision following a lumpectomy was reduced by 51 percent when MarginProbe was used during the initial procedure.

The research, published in Archives of Gynecology and Obstetrics, was led by Professor Jens-Uwe Blohmer, director of the Department of Gynecology and the breast center of the Charité, Charité – Universitätsmedizin Berlin. The study also found that patients with ductal invasive cancer had an 89.8 reduction in re-excisions. Dramatic re-excision reduction was also shown for DCIS patients and for with lobular invasive carcinoma.

The study, which was conducted by surgeons J.U. Blohmer, J. Tanko, J. Kueper, J. Gross, A. Machleidt and R. Volker and can be found online at (

Visit for more information on the Miami Breast Cancer Conference.

About Dune Medical Devices

Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications.

Dune Medical Devices is a privately held company with offices in the U.S. and Israel. For more
information, please visit